Insider Trading History of Fridriksdottir Hafrun


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Fridriksdottir Hafrun since year 2005. The trader's CIK number is 1561458. At the time of the last reporting, Fridriksdottir Hafrun was the Sr VP, Global Generics R&D of Teva Pharmaceutical Industries Ltd . (stock ticker symbol TEVA). See this page for all insider trading activities at Teva Pharmaceutical Industries Ltd .

Note that in the past Fridriksdottir Hafrun also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Fridriksdottir Hafrun since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2019-03-17 TEVA Teva Pharmaceutical Industries Ltd Option Ex 1,012 .00 0
2019-03-18 TEVA Teva Pharmaceutical Industries Ltd Sale 356 16.62 5,918
2019-03-04 TEVA Teva Pharmaceutical Industries Ltd Option Ex 1,165 .00 0
2019-03-04 TEVA Teva Pharmaceutical Industries Ltd Sale 409 16.88 6,905
2019-02-14 TEVA Teva Pharmaceutical Industries Ltd Option Ex 5,353 .00 0
2019-02-14 TEVA Teva Pharmaceutical Industries Ltd Sale 1,841 17.67 32,528
2019-01-02 TEVA Teva Pharmaceutical Industries Ltd Sale 1,643 15.70 25,800
2018-12-31 TEVA Teva Pharmaceutical Industries Ltd Option Ex 4,640 .00 0
2018-11-30 TEVA Teva Pharmaceutical Industries Ltd Option Ex 2,711 .00 0
2018-11-30 TEVA Teva Pharmaceutical Industries Ltd Sale 933 21.76 20,303
2018-03-17 TEVA Teva Pharmaceutical Industries Ltd Option Ex 1,012 .00 0
2018-03-19 TEVA Teva Pharmaceutical Industries Ltd Sale 348 17.88 6,221
2018-03-04 TEVA Teva Pharmaceutical Industries Ltd Option Ex 1,165 .00 0
2018-03-05 TEVA Teva Pharmaceutical Industries Ltd Option Ex 3,432 .00 0
2013-09-30 ACT Watson Pharmaceuticals Inc Option Ex 5,110 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Fridriksdottir Hafrun (Sr VP, Global Generics R&D of Teva Pharmaceutical Industries Ltd at the time of this reporting) see the Securities and Exchange Commission (SEC) website.